Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 3, 2016, Pages 281-289

  Gupta, Pranav ^a   Jani, Khushboo A ^a   Yang, Dong Hua ^a   Sadoqi, Mostafa ^a   Squillante, Emilio ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

carriers; metabolism; modulators; multi drug resistance; nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CERAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; NANOCARRIER; NANOPARTICLE; POLYMERIC NANOPARTICLE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL METABOLISM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; MICELLE; NEOPLASM; PROTEIN TARGETING; REVIEW; ANIMAL; BIOAVAILABILITY; DRUG DESIGN; DRUG RESISTANCE; MULTIDRUG RESISTANCE; NEOPLASMS; PARTICLE SIZE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE;

EID: 84959169395     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1145655     Document Type: Review

References (86)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65 (1): 5-29.
2. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009; 61 (13): 1203-1213.
3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53: 615-27.
4. Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv Exp Med Biol. 2007; 593: 95-104.
5. Anreddy N, Gupta P, Kathawala RJ, et al. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. Molecules. 2014; 19 (9): 13848-13877.
6. Kathawala RJ, Sodani K, Chen K, et al. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Mol Cancer Ther. 2014; 13 (3): 714-723.
7. Wang YJ, Kathawala RJ, Zhang YK, et al. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem Pharmacol. 2014; 90 (4): 367-378.
8. Kathawala RJ, Wei L, Anreddy N, et al. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget. 2015; 6 (1): 510-521.
9. Sodani K, Patel A, Anreddy N, et al. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014; 89 (1): 52-61.
10. Wang DS, Patel A, Shukla S, et al. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget. 2014; 5 (12): 4529-4542.
11. Zhang H, Zhang YK, Wang YJ, et al. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. Cancer Sci. 2014; 105 (8): 1071-1078.
12. Kapse-Mistry S, Govender T, Srivastava R, et al. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014; 5: 159.
13. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14 (5): 1310-1316.
14. Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011; 14 (3): 150-63.
15. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today. 2012; 17 (17-18): 1044-1052.
16. Huang Y, Wang YJ, Wang Y, et al. Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. Acta Biomater. 2015;25:268-283.
17. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53 (2): 283-318.
18. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003; 42 (6): 463-478.
19. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55 (3): 329-347.
20. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond). 2010; 5 (4): 597-615.
21. Tang MF, Lei L, Guo SR, et al. Recent progress in nanotechnology for cancer therapy. Chin J Cancer. 2010; 29 (9): 775-780.
22. Xue X, Liang XJ. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer. 2012; 31 (2): 100-109.
23. Saba NF, Wang X, Müller S, et al. Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head Neck. 2009; 31 (4): 475-481.
24. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-Aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103 (16): 6315-6320.
25. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med. 2006; 47 (4): 668-678.
26. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-Aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 64 (21): 7668-7672.
27. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005; 2 (5): 373-383.
28. Narayanan NK, Nargi D, Randolph C, et al. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer. 2009; 125 (1): 1-8.
29. Tekade RK, Dutta T, Gajbhiye V, et al. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul. 2009; 26 (4): 287-296.
30. Shieh MJ, Hsu CY, Huang LY, et al. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release. 2011; 152 (3): 418-425.
31. Wu J, Lu Y, Lee A, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 2007; 10 (3): 350-357.
32. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004; 22 (22): 4523-4531.
33. Xu Z, Gu W, Huang J, et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm. 2005; 288 (2): 361-368.
34. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105 (45): 17356-17361.
35. Shin HC, Alani AW, Cho H, et al. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm. 2011; 8 (4): 1257-1265.
36. Wang F, Zhang D, Zhang Q, et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials. 2011; 32 (35): 9444-9456.
37. Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release. 2008; 130 (2): 107-114.
38. Li R, Wu R, Zhao L, et al. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano. 2010; 4 (3): 1399-1408.
39. Feazell RP, Nakayama-Ratchford N, Dai H, et al. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc. 2007; 129 (27): 8438-8439.
40. Markman JL, Rekechenetskiy A, Holler E, et al. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013; 65 (13-14): 1866-79.
41. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23 (31): 7794-7803.
42. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005; 23 (31): 7785-7793.
43. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006; 17 (8): 1263-1268.
44. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003; 8 (24): 1112-1120.
45. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010; 15 (5-6): 171-185.
46. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev. 2005; 57 (15): 2106-2129.
47. Ji SR, Liu C, Zhang B, et al. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta. 2010; 1806 (1): 29-35.
48. Fabbro C, Ali-Boucetta H, Da Ros T, et al. Targeting carbon nanotubes against cancer. Chem Commun (Camb). 2012; 48 (33): 3911-3926.
49. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2 (1): 48-58.
50. Kathawala RJ, Gupta P, Ashby CR, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015; 18: 1-17.
51. Zhang YK, Wang YJ, Gupta P, et al. Multidrug resistance proteins (MRPs) and cancer therapy. Aaps J. 2015;17(4):802-812.
52. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012; 83 (8): 1104-1111.
53. Iyer AK, Singh A, Ganta S, et al. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013; 65 (13-14): 1784-1802.
54. Yadav S, Van Vlerken LE, Little SR, et al. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol. 2009; 63 (4): 711-722.
55. Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010; 31 (2): 358-365.
56. Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat. 2010; 13 (4-5): 109-118.
57. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm. 2009; 367 (1-2): 195-203.
58. Chen Y, Bathula SR, Li J, et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem. 2010; 285 (29): 22639-22650.
59. Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002; 19 (9): 1310-1316.
60. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol. 2009; 27 (7): 643-651.
61. Kuo W-S, Ku Y-C, Sei H-T, et al. Paclitaxel-loaded stabilizer-free poly(D,L-lactide-co-glycolide) nanoparticles conjugated with quantum dots for reversion of anti-cancer drug resistance and cancer cellular imaging. J Chin Chem Soc. 2009; 56 (5): 923-934.
62. Khdair A, Chen D, Patil Y, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010; 141 (2): 137-144.
63. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981; 41 (5): 1967-1972.
64. Patel NR, Pattni BS, Abouzeid AH, et al. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev. 2013; 65 (13-14): 1748-1762.
65. Yu DF, Wu FR, Liu Y, et al. Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. Biomed Pharmacother. 2013; 67 (7): 615-619.
66. Jagani HV, Josyula VR, Palanimuthu VR, et al. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-Apoptotic Bcl-2 through chitosan coating. Eur J Pharm Sci. 2013; 48 (4-5): 611-618.
67. Kim E, Jung Y, Choi H, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 2010; 31 (16): 4592-4599.
68. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond). 2008; 3 (6): 761-776.
69. Devalapally H, Duan Z, Seiden MV, et al. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res. 2008; 14 (10): 3193-3203.
70. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8 (1): 33-40.
71. Luqman S, Pezzuto JM. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res. 2010; 24 (7): 949-963.
72. Schwartz SA, Hernandez A, Mark Evers B. The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surg Oncol. 1999; 8 (3): 143-153.
73. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010; 79 (3): 330-338.
74. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007; 5: 3.
75. Xiao J, Duan X, Yin Q, et al. The inhibition of metastasis and growth of breast cancer by blocking the NF-B signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. Biomaterials. 2013; 34 (21): 5381-5390.
76. Patil Y, Sadhukha T, Ma L, et al. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009; 136 (1): 21-29.
77. Singhal SS, Yadav S, Vatsyayan R, et al. Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis. Cancer Lett. 2009; 283 (2): 152-158.
78. Dalton S. Cell cycle regulation of the human cdc2 gene. Embo J. 1992; 11 (5): 1797-1804.
79. Xu Z, Zhang Z, Chen Y, et al. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials. 2010; 31 (5): 916-922.
80. Zhang L, Radovic-Moreno AF, Alexis F, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-Aptamer bioconjugates. ChemMedChem. 2007; 2 (9): 1268-1271.
81. Kathawala RJ, Chen JJ, Zhang YK, et al. Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol. 2014; 44 (5): 1634-1642.
82. Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012; 162 (1): 45-55.
83. Xiong XB, Ma Z, Lai R, et al. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials. 2010; 31 (4): 757-768.
84. Yu Y, Wang ZH, Zhang L, et al. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials. 2012; 33 (6): 1808-20.
85. Wang XX, Li YB, Yao HJ, et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials. 2011; 32 (24): 5673-5687.
86. Sancho P, Galeano E, Nieto E, et al. Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leuk Res. 2007; 31 (7): 969-978.